WVE 120102

Drug Profile

WVE 120102

Alternative Names: WVE-120102

Latest Information Update: 04 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator WaVe life Sciences
  • Class Antisense oligonucleotides; Neuroprotectants
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Huntington's disease

Most Recent Events

  • 18 Jul 2017 Phase-I/II clinical trials in Huntington's disease in Canada (Intrathecal)
  • 16 Mar 2017 Preclinical trials in Huntington's disease in USA and Japan (Intrathecal)
  • 06 Jan 2017 WaVe Life Sciences announces intention to submit Clinical Trial Application (CTA) in Europe in the first half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top